Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small, dense low-density lipoprotein (sdLDL) is a subclass of LDL particles characterized by their smaller size and higher density compared to larger LDL particles. sdLDL is considered the most atherogenic form of LDL due to its increased propensity to penetrate the arterial wall, become oxidized, and contribute to the development of atherosclerosis. Elevated levels of sdLDL are strongly associated with an increased risk for cardiovascular diseases.
Targets lipid metabolism to reduce LDL cholesterol and/or increase LDL receptor activity, or prevent cholesterol absorbtion, ultimately aiming to reduce sdLDL levels and prevent atherosclerosis.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small, Dense Low-Density Lipoprotein (sdLDL).